August 11, 2020 Necrotizing Enterocolitis: Using Regulatory Science and Drug Development to Improve Outcomes , September 2019
C-Path Partners with CHDR to Expand Global Collaborations The Critical Path Institute and the Centre for Human Drug Research (CHDR) have joined forces to expand global collaborations for b
C-Path’s PSTC, D-RSC Receive Positive FDA Response for Drug-Induced Skeletal Muscle Injury Biomarkers Safety biomarkers aim to provide an additional tool for detecting acute drug-induced skeletal muscle injury in phase 1 clinical tr
C-Path’s PSTC, D-RSC Receive Positive FDA Response to Plan for Liver Safety Biomarker Biomarker aims to provide an additional tool for detecting the onset of hepatic injury in clinical trials involving patients with
C-Path Data Collaboration Center Analytics Team Wins Metadata Automation DREAM Challenge TUCSON, Ariz., July 14, 2020 — Tucson-based Critical Path Institute (C-Path) today proudly announced that the analytics team f
C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19 Clinicians to report novel uses of existing drugs through FDA-NCATS CURE ID Mobile App. TUCSON, Ariz., June 23, 2020 — As millio
June 19, 2020 Method of Blood Pressure Measurement in Neonates and Infants: A Systematic Review and Analysis
June 20, 2020 C-Path’s Transplant Therapeutics Consortium Receives Acceptance of Letter of Intent for iBox Scoring System (Composite Biomarker Panel) as a Reasonably Likely Surrogate Endpoint Biomarker aims to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplan
